Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Angewandte Chemie (International Ed. in English)|March 5, 2009
Unprecedented selectivity via electronic substrate recognition in the 1,4-addition to cyclic olefins using a chiral disulfoxide rhodium catalystJustus J Bürgi, Ronaldo Mariz, Michele Gatti, et al.Journal of Chemical Information and Modeling|November 15, 2011
Discovery of α7-nicotinic receptor ligands by virtual screening of the chemical universe database GDB-13Lorenz C Blum, Ruud van Deursen, Sonia Bertrand, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|November 16, 2010
C2-symmetric chiral disulfoxide ligands in rhodium-catalyzed 1,4-addition: from ligand synthesis to the enantioselection pathwayRonaldo Mariz, Albert Poater, Michele Gatti, et al.ACS Chemical Neuroscience|March 6, 2014
Discovery of potent positive allosteric modulators of the α3β2 nicotinic acetylcholine receptor by a chemical space walk in ChEMBLJustus J Bürgi, Mahendra Awale, Silvan D Boss, et al.Frontiers in Cardiovascular Medicine|December 19, 2022
Mild COVID-19 induces early, quantifiable, persistent troponin I elevations in elder menJustus J Bürgi, Matthias Rösslein, Oliver Nolte, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|September 7, 2025
Understanding the kinetics of macrophage uptake and the metabolic fate of iron-carbohydrate complexes used for iron deficiency anemia treatmentStephanie Eitner, Vera M Kissling, Alexandra Rippl, et al.Alimentary Pharmacology & Therapeutics|October 29, 2022
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2Simon Woelfel, Joel Dütschler, Marius König, et al.Vaccines|July 30, 2025
XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.Alimentary Pharmacology & Therapeutics|October 29, 2024
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.Vaccines|July 27, 2024
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.Pageof 2